Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57,835 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer.
Xu J, Wan R, Cai Y, Cai S, Wu L, Li B, Duan J, Cheng Y, Li X, Wang X, Han L, Wu X, Fan Y, Yu Y, Lv D, Shi J, Huang J, Zhou S, Han B, Sun G, Guo Q, Ji Y, Zhu X, Hu S, Zhang W, Wang Q, Jia Y, Wang Z, Song Y, Wu J, Shi M, Li X, Han Z, Liu Y, Yu Z, Liu AW, Wang X, Zhou C, Zhong D, Miao L, Zhang Z, Zhao H, Yang J, Wang D, Wang Y, Li Q, Zhang X, Ji M, Yang Z, Cui J, Gao B, Wang B, Liu H, Nie L, He M, Jin S, Gu W, Shu Y, Zhou T, Feng J, Yang X, Huang C, Zhu B, Yao Y, Yu J, Yao S, Shen R, Wang Z, Wang J. Xu J, et al. Among authors: huang c, huang j. Cancer Cell. 2024 Sep 9;42(9):1598-1613.e4. doi: 10.1016/j.ccell.2024.08.013. Cancer Cell. 2024. PMID: 39255777 Free article.
Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study.
Zhang XD, Shu YQ, Liang J, Zhang FC, Ma XZ, Huang JJ, Chen L, Shi GM, Cao WG, Guo CY, Shen L, Jin ML. Zhang XD, et al. Among authors: huang jj. Chin J Cancer Res. 2012 Dec;24(4):291-8. doi: 10.3978/j.issn.1000-9604.2012.08.04. Chin J Cancer Res. 2012. PMID: 23359329 Free PMC article.
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators. Schuler M, et al. Ann Oncol. 2016 Mar;27(3):417-23. doi: 10.1093/annonc/mdv597. Epub 2015 Dec 8. Ann Oncol. 2016. PMID: 26646759 Free PMC article. Clinical Trial.
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.
Ouyang X, Shi M, Jie F, Bai Y, Shen P, Yu Z, Wang X, Huang C, Tao M, Wang Z, Xie C, Wu Q, Shu Y, Han B, Zhang F, Zhang Y, Hu C, Ma X, Liang Y, Wang A, Lu B, Shi Y, Chen J, Zhuang Z, Wang J, Huang J, Wang C, Bai C, Zhou X, Li Q, Chen F, Yu H, Feng J. Ouyang X, et al. Among authors: huang c, huang j. Invest New Drugs. 2018 Apr;36(2):315-322. doi: 10.1007/s10637-017-0536-y. Epub 2017 Nov 14. Invest New Drugs. 2018. PMID: 29134432 Clinical Trial.
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China.
Yang Y, Yang N, Wu L, Ouyang Q, Fang J, Li J, Liao W, Cai K, Huang J, Li J, Zhang Y, Wang X, Zhang H, Xu N, Zhao Q, Hu X, Li W, Zhong W, Zhong D, Cheng G, Ye S, Zhong M, Wang D, Liu H, Zheng J, Liu X, Xu H, Zhang L. Yang Y, et al. Among authors: huang j. Chin Clin Oncol. 2020 Oct;9(5):68. doi: 10.21037/cco-20-160. Chin Clin Oncol. 2020. PMID: 33161724 Free article.
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. Shaw AT, et al. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.
57,835 results
You have reached the last available page of results. Please see the User Guide for more information.